Validation of LC–MS/MS Bioanalytical Methods for Protein Therapeutics
Authors:
- 1 July 2014
- journal article
- Published by Taylor & Francis in Bioanalysis
- Vol. 6 (13) , 1739-1742
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- LC–MS/MS of Large Molecules in A Regulated Bioanalytical Environment – Which Acceptance Criteria to Apply?Bioanalysis, 2013
- Bioanalytical LC–MS/MS of protein-based biopharmaceuticalsJournal of Chromatography B, 2013
- Attribution of the discrepancy between ELISA and LC-MS/MS assay results of a PEGylated scaffold protein in post-dose monkey plasma samples due to the presence of anti-drug antibodiesAnalytical and Bioanalytical Chemistry, 2011
- Absolute Quantitation of Protein Therapeutics in Biological Matrices by Enzymatic Digestion and LC–MSBioanalysis, 2011
- Bioanalytical Approaches to Analyzing Peptides and Proteins by LC–MS/MSBioanalysis, 2011
- Evaluation of Large Scale Quantitative Proteomic Assay Development Using Peptide Affinity-based Mass SpectrometryMolecular & Cellular Proteomics, 2011
- Absolute Quantification of a Therapeutic Domain Antibody Using Ultra-Performance Liquid Chromatography–Mass Spectrometry and ImmunoassayBioanalysis, 2010
- Critical Comparison of MS and Immunoassays for the Bioanalysis of Therapeutic AntibodiesBioanalysis, 2009
- Quantitative Bioanalytical Methods Validation and Implementation: Best Practices for Chromatographic and Ligand Binding AssaysPharmaceutical Research, 2007